Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Physician calls for "radical new approach" to MS after positive Alemtuzumab Phase II 5-Year review

This article was originally published in Scrip

Executive Summary

A lead investigator in the Phase 2 CAMMS223 trial of Genzyme's alemtuzumab (CamPath-H1) has called for " a radical new approach" to treatment of multiple sclerosis on the basis of 5-year follow up data presented on 14 October at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) International Conference in Goteborg, Sweden. Dr Alasdair Coles from the Department of Clinical Neurosciences, University of Cambridge hopes that MS physicians will look at the data from the study and move quickly to aggressive treatments such as alemtuzumab before overt and severe disability emerges, rather than adopting the "wait-and-see" approach with MS patients.

You may also be interested in...

Gender Diversity In Pharma: Caught Between Desire And Reality

Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete. 

Women In High Places: Slow Progress In Pharma

With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.

Stock Scan April 2018: Pharma's Fizz Falls Flat

In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts